BR112018013356A2 - sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica - Google Patents

sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica

Info

Publication number
BR112018013356A2
BR112018013356A2 BR112018013356A BR112018013356A BR112018013356A2 BR 112018013356 A2 BR112018013356 A2 BR 112018013356A2 BR 112018013356 A BR112018013356 A BR 112018013356A BR 112018013356 A BR112018013356 A BR 112018013356A BR 112018013356 A2 BR112018013356 A2 BR 112018013356A2
Authority
BR
Brazil
Prior art keywords
hydrochloride salt
pharmaceutical composition
crystalline forms
crystalline form
hydrochloride
Prior art date
Application number
BR112018013356A
Other languages
English (en)
Inventor
Cheol Kim Hee
Sook Oh Hee
Young Jeon Ji
Ouk Baek Jong
Young Jang Sun
Hee Ha Tae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112018013356A2 publication Critical patent/BR112018013356A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

a presente invenção se refere a uma forma cristalina de um sal de cloridrato de n-(3-(2-(4-(4-metilpiperazin-1-il)fenilamino)tieno[3,2-d]pirimidin-4-iloxi)fenil)acrilamida e uma composição farmacêutica que contém a mesma. a forma cristalina do sal de cloridrato do composto pode ser facilmente usada para preparar uma composição farmacêutica que contém a mesma como um ingrediente ativo.
BR112018013356A 2015-12-31 2016-12-30 sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica BR112018013356A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150190853 2015-12-31
KR20160065977 2016-05-27
PCT/KR2016/015535 WO2017116192A1 (en) 2015-12-31 2016-12-30 Crystalline forms of hydrochloride salts of thienopyrimidine compound

Publications (1)

Publication Number Publication Date
BR112018013356A2 true BR112018013356A2 (pt) 2018-12-04

Family

ID=59225204

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013356A BR112018013356A2 (pt) 2015-12-31 2016-12-30 sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica

Country Status (16)

Country Link
US (1) US11008333B2 (pt)
EP (1) EP3380481A4 (pt)
JP (1) JP6907439B2 (pt)
KR (1) KR20180089903A (pt)
CN (1) CN108473506B (pt)
AU (1) AU2016382384A1 (pt)
BR (1) BR112018013356A2 (pt)
CA (1) CA3010176A1 (pt)
HK (1) HK1252841A1 (pt)
IL (1) IL259981A (pt)
MX (1) MX2018008006A (pt)
PH (1) PH12018501314A1 (pt)
RU (1) RU2018122050A (pt)
SG (1) SG11201804858YA (pt)
TW (1) TW201726685A (pt)
WO (1) WO2017116192A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200114776A (ko) * 2019-03-29 2020-10-07 한미약품 주식회사 퓨로피리미딘 화합물의 산 부가염의 결정형

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
LT2975042T (lt) 2010-06-23 2019-01-25 Hanmi Science Co., Ltd. Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
KR20140118575A (ko) * 2013-03-29 2014-10-08 한미약품 주식회사 신규한 하이드록사메이트 유도체
WO2015112705A2 (en) 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
WO2016201370A1 (en) * 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016382385A1 (en) 2015-12-31 2018-07-12 Hanmi Pharm. Co., Ltd. Crystalline forms of thienopyrimidine compound

Also Published As

Publication number Publication date
MX2018008006A (es) 2019-03-14
CN108473506A (zh) 2018-08-31
HK1252841A1 (zh) 2019-06-06
IL259981A (en) 2018-07-31
SG11201804858YA (en) 2018-07-30
TW201726685A (zh) 2017-08-01
CA3010176A1 (en) 2017-07-06
RU2018122050A3 (pt) 2020-02-28
JP2019500384A (ja) 2019-01-10
AU2016382384A1 (en) 2018-07-12
US20200270268A1 (en) 2020-08-27
RU2018122050A (ru) 2020-01-31
CN108473506B (zh) 2021-08-17
WO2017116192A1 (en) 2017-07-06
EP3380481A1 (en) 2018-10-03
KR20180089903A (ko) 2018-08-09
PH12018501314A1 (en) 2019-02-27
EP3380481A4 (en) 2019-05-15
JP6907439B2 (ja) 2021-07-21
US11008333B2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CU20160006A7 (es) Derivados de piperidinil-indol como inhibidores de factor de complemento b
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
UY37205A (es) Inhibidores de bromodominios
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112014011938A2 (pt) combinação de formulação de dois compostos antivirais
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
CR20150481A (es) Composición farmacéutica de clorhidrato de s-ketamina
CR20150480A (es) Composición farmacéutica de clorhidrato de s-cetamina
TW201613945A (en) Compounds and compositions as kinase inhibitors
UY35275A (es) Derivados de aminopirazina
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
BR112017004948A2 (pt) formulação farmacêutica.
CL2019002986A1 (es) Nuevo compuesto sólido cristalino clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
BR112018013364A2 (pt) forma cristalina e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements